San Diego, CA, United States of America

Fen Wang


Average Co-Inventor Count = 8.0

ph-index = 3

Forward Citations = 39(Granted Patents)


Company Filing History:


Years Active: 2005-2008

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Fen Wang: Innovator in Protein Kinase Inhibitors

Introduction

Fen Wang is a notable inventor based in San Diego, CA (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of tricyclic compounds that serve as protein kinase inhibitors. With a total of 3 patents, his work focuses on enhancing the efficacy of anti-neoplastic agents and radiation therapy.

Latest Patents

Fen Wang's latest patents include innovative formulations of tricyclic compounds that inhibit protein kinases, such as CHK-1. These compounds are designed to be used as single agents or in combination with anti-neoplastic agents or therapeutic radiation. The pharmaceutical compositions containing effective amounts of these compounds or their salts are aimed at treating various diseases or conditions, particularly cancers. His inventions are pivotal in advancing cancer treatment methodologies.

Career Highlights

Fen Wang is currently associated with Agouron Pharmaceuticals, Inc., where he continues to push the boundaries of pharmaceutical research. His work has been instrumental in developing new therapeutic strategies that leverage the potential of tricyclic compounds in oncology.

Collaborations

Fen Wang has collaborated with notable colleagues, including Suzanne Pritchett Benedict and Michael John Bennett. These collaborations have fostered a productive environment for innovation and research in the pharmaceutical sector.

Conclusion

Fen Wang's contributions to the field of protein kinase inhibitors and cancer treatment exemplify the impact of innovative research in pharmaceuticals. His work continues to inspire advancements in therapeutic strategies for combating cancer.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…